LYNPARZA™ (olaparib) Approved for the Treatment of Advanced Relapsed Ovarian Cancer in Patients with Germline BRCA Mutations, Available Exclusively at Biologics, Inc.

Biologics, an integrated oncology services company, is pleased to announce that AstraZeneca has selected the company to be the exclusive distribution network provider for LYNPARZA (olaparib). LYNPARZA was approved by the U.S. Food and Drug Administration on December 19, 2014 as the first monotherapy for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy.

Recognized for its high-touch patient care model, Biologics’ Oncology Pharmacy and Patient Access Services group provides a dedicated, clinically relevant team to support the clinical, financial and emotional needs of specific patient populations.

“We are thrilled to be the exclusive provider for this groundbreaking therapy,” said Dan Duffy, chief business development officer at Biologics. “We are honored to be a part of this important launch for AstraZeneca, and look forward to helping support patients in need of this important therapy.”

In addition to developing unique patient care plans that help support compliance, Biologics will perform benefits investigation, benefits verification and prior authorization services to help streamline access to therapy and alleviate the administration burden on providers. The team also helps facilitate copayment or coinsurance assistance for patients.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. To send prescriptions via eScribe, physicians may search for Biologics within their EMR system.

• Pharmacy name: Biologics
  
• Street address: 120 Weston Oaks Court, Cary, NC 27513
  
• NCPDP: 3430369
  
• NPI: 1487640314

About Biologics: Biologics, Inc. is an oncology services company that empowers healthcare providers, payors and biopharma to optimize cancer care for the best possible outcomes – clinical, financial and emotional. Unifying fragmented healthcare services, Biologics brings efficiency and humanity to oncology care management by focusing on the patient’s best interest as the surest path to managing cost and risk. Biologics is at the center of a rapidly changing oncology environment and supports patients across all treatment modalities, while providing clinical outcomes and informatics reporting that allow for informed decision making. Since it was founded in 1994, Biologics has been dedicated to improving the lives of those fighting cancer. Privately held, Biologics maintains headquarters and operations in Cary, North Carolina. Visit biologicsinc.com or follow us on Twitter (@BiologicsInc).